EGFR and lung adenocarcinoma: However, since genetic testing-based therapy was put into the guidelines for treating advanced lung adenocarcinoma, the challenge lies in the availability of rebiopsy tissues from patients who failed to respond to treatment with first or second-generation EGFR-TKIs.